Pellet technology.

Mayne Pharma pelleting technology and processesMayne Pharma pelleting technology and processes

Pellet (or bead) technology allows a variety of different drug delivery profiles to be achieved by coating a ‘core’ of drug and excipient with various polymers. The drug cores are generally spheroidal in shape and have a diameter in the range of 300 to 1,700 µm. In order to generate the spheroidal particles, there are two main types of processes used:

  • The first, extrusion granulation, granulates API with excipients, which is extruded to form a core then coated by polymers. This process allows drug potencies up to 90%.
  • The second process is known as spheronization, where drug particles are fixed to the outside of a seed core, typically sugar, with the aid of a binder. The core is coated with a polymer. This process provides a very tight size distribution of pellets. Drug potencies up to 60% are possible.


Pellet technology has successfully been applied to a number of proprietary pharmaceuticals with modified release profiles. These include:

  • ERYC® (delayed-release erythromycin)
  • DORYX® (delayed-release doxycycline)
  • KADIAN® (extended-release morphine)
  • ASTRIX® (delayed-release low-dose aspirin)


How may we help you?

Fill out the form below or call us on +61 8 8209 2453 to discuss your pharmaceutical project needs.

Please note no enquiries for job applications are accepted via this form. Please see here for the current job opportunities available at Mayne Pharma.